LOTTE BIOLOGICS, the new biologics business of the LOTTE group, signed a Memorandum of Understanding (MoU) with the leading science and technology company MilliporeSigma, (the U.S. and Canada Life Science business of Merck KGaA), outlining a collaboration to establish LOTTE’s Biologics manufacturing capabilities in the USA.  With this agreement, MilliporeSigma will be the first supplier to provide LOTTE with consulting, training, technical expertise, products, technologies, and manufacturing solutions. 

The Life Science business of Merck KGaA, Darmstadt, Germany has well over 30 years’ experience in process development and GMP manufacturing.  The company has helped bring more than 280 biologics to market and has released more than 100 GMP drug substances since 2012 across a range of molecules and scales.